GlassScriptPhysician profile
Carl J Kinzel
NPI 1992983209
$11,976.30
in general payments reported to CMS, 2019-2025
49 companies · $1,882 in 2025
The $1,882 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $1,020 · 2021: $1,331 · 2022: $2,372 · 2023: $2,208 · 2024: $2,362 · 2025: $1,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,451.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,365.73 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $1,342.31 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $851.97 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $842.03 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $770.70 | 2019-2025 | |
| Abbvie INC. | $764.41 | 2019-2025 | |
| Glaxosmithkline, LLC. | $746.65 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $506.38 | 2019-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $372.61 | 2022-2025 | |
| Astellas Pharma US INC | $369.06 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.65 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Dexcom, INC. | $219.56 | 2022-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $201.64 | 2023-2025 | Rexulti |
| Insulet Corporation | $190.17 | 2024-2025 | Omnipod |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $174.13 | 2023-2025 | Caplyta |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Kinzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.